TD Asset Management
CYTK icon

TD Asset Management’s Cytokinetics CYTK Stock Holding History

TD Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.8M Sell
385,130
-35,716
-8% -$2.56M 0.03% 398
2026
Q1 		$27.7M Sell
420,846
-123,164
-23% -$7.83M 0.02% 445
2025
Q4 		$34.6M Sell
544,010
-127,770
-19% -$7.95M 0.03% 393
2025
Q3 		$36.9M Buy
671,780
+127,488
+23% +$5.25M 0.03% 382
2025
Q2 		$18M Buy
544,292
+97,464
+22% +$3.39M 0.02% 512
2025
Q1 		$18M Sell
446,828
-77,806
-15% -$3.58M 0.02% 518
2024
Q4 		$24.7M Sell
524,634
-36,384
-6% -$1.89M 0.02% 474
2024
Q3 		$29.4M Buy
561,018
+200,420
+56% +$11.2M 0.03% 411
2024
Q2 		$19.5M Buy
360,598
+76,078
+27% +$4.59M 0.02% 499
2024
Q1 		$19.9M Buy
284,520
+102,480
+56% +$7.93M 0.02% 488
2023
Q4 		$15.2M Buy
182,040
+82,400
+83% +$2.98M 0.01% 530
2023
Q3 		$2.94M Buy
99,640
+26,297
+36% +$876K ﹤0.01% 853
2023
Q2 		$2.39M Sell
73,343
-600
-0.8% -$22.2K ﹤0.01% 923
2023
Q1 		$2.6M Buy
73,943
+22,800
+45% +$930K ﹤0.01% 905
2022
Q4 		$2.34M Buy
51,143
+12,600
+33% +$542K ﹤0.01% 940
2022
Q3 		$1.89M Buy
38,543
+8,600
+29% +$414K ﹤0.01% 1019
2022
Q2 		$1.18M Sell
29,943
-557
-2% -$22.4K ﹤0.01% 1150
2022
Q1 		$1.12M Buy
30,500
+22,100
+263% +$785K ﹤0.01% 1211
2021
Q4 		$383K Buy
+8,400
New +$324K ﹤0.01% 1409
2020
Q4 		– Sell
-35,700
Closed -$773K – 1445
2020
Q3 		$773K Buy
+35,700
New +$835K ﹤0.01% 1135
2018
Q1 		– Sell
-18,300
Closed -$149K – 1347
2017
Q4 		$149K Hold
18,300
– – ﹤0.01% 1313
2017
Q3 		$265K Buy
+18,300
New +$250K ﹤0.01% 1254
2013
Q4 		– Sell
-18,868
Closed -$143K – 1296
2013
Q3 		$143K Buy
+18,868
New +$202K ﹤0.01% 1228

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Asset Management's CYTK Position: Q2 2026 in Review

TD Asset Management reduced its Cytokinetics (CYTK) stake by 8.5% in Q2 2026, selling an estimated $2.56M and leaving 385,130 shares worth $32.8M. The position accounts for 0.03% of the portfolio, ranked #398.

TD Asset Management first reported a position in CYTK in Q3 2013 and has held it in 23 quarters since. The position peaked at $36.9M in Q3 2025. 329 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • TD Asset Management held 385,130 shares of Cytokinetics worth $32.8M as of Q2 2026.
  • TD Asset Management sold 35,716 Cytokinetics shares in Q2 2026, an estimated $2.56M.
  • Cytokinetics made up 0.03% of TD Asset Management's portfolio in Q2 2026, its #398 holding.
  • TD Asset Management first reported a position in Cytokinetics in Q3 2013 and has held it in 23 quarters since.
  • TD Asset Management's Cytokinetics position peaked at $36.9M in Q3 2025.
  • 329 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.